Cell- and biomarker-based assays for predicting nephrotoxicity
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Drug-induced nephrotoxicity contributes to the failure rate of investigational drugs during clinical trials. We are still not able to accurately predict drug-induced nephrotoxicity during early drug discovery and development. There is an urgent need for a robust screening system that can identify nephrotoxic compounds before they reach the clinic. AREAS COVERED: This review discusses traditional and emerging kidney injury biomarkers that are used for the determination of nephrotoxicity and for evaluation and diagnosis of other kidney diseases. The potential for in vivo biomarkers to predict renal toxicity in high-throughput in vitro screening assays is discussed. We also compare cell types and highlight novel three-dimensional (3D) culture technologies with potential for in vitro prediction of nephrotoxicity. EXPERT OPINION: Traditional cell culture methods and cytotoxicity assays are well established as in vitro tests for nephrotoxicity but the correlation with in vivo results is extremely poor. Recently validated renal biomarkers show promise for early in vivo detection of nephrotoxicity, but have yet to be successfully applied for in vitro prediction of drug-induced nephrotoxicity. Advanced culture technologies 'kidney-on-a-chip' and 3D culture can produce biomarker signatures from relevant kidney cell types that show promise as better predictive systems.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Assessing Kidney Function — Measured and Estimated Glomerular Filtration Rate
Stevens, L. A., Coresh, J., Greene, T., & Levey, A. S. (2006) · New England Journal of Medicine · doi:10.1056/nejmra054415 · Cited by 2,952 · cited 1×
“73 m(2), and changes in this measure can be used as a surrogate indicator of CKD stages [13].”
BackgroundDiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)
Kellum, J. A., Lameire, N., & for the KDIGO AKI Guideline Work Group (2013) · Critical Care · doi:10.1186/cc11454 · Cited by 2,827
Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron
Flo, T. H., Smith, K. D., Sato, S., Rodriguez, D. J., Holmes, M. A., Strong, R. K., Akira, S., & Aderem, A. (2004) · Nature · doi:10.1038/nature03104 · Cited by 1,877 · cited 1×
“5 NGAL Another well-known biomarker is the cytosolic protein NGAL [41,42], which is part of the lipocalin superfamily involved in regulating immune responses, transporting iron and modulating cell growth and metabolism [43,44].”
BackgroundMishra, J., Ma, Q., Prada, A., Mitsnefes, M., Zahedi, K., Yang, J., Barasch, J., & Devarajan, P. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000088027.54400.c6 · Cited by 1,749 · cited 1×
“Upregulated NGAL levels were detected in the urine of mice on day 1 in a study that administered cisplatin, a much earlier response compared to the elevation of SCr, BUN and histopathological changes that were not displayed until day 3 [46].”
BackgroundLessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4309 · Cited by 1,344 · cited 1×
“Similarly, 52% of projects failed in the clinical phase due to safety, with 9% due to renal issues [8].”
BackgroundDual Action of Neutrophil Gelatinase–Associated Lipocalin
Schmidt-Ott, K. M., Mori, K., Li, J. Y., Kalandadze, A., Cohen, D. J., Devarajan, P., & Barasch, J. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006080882 · Cited by 772 · cited 1×
“5 NGAL Another well-known biomarker is the cytosolic protein NGAL [41,42], which is part of the lipocalin superfamily involved in regulating immune responses, transporting iron and modulating cell growth and metabolism [43,44].”
BackgroundAcute kidney injury-epidemiology, outcomes and economics
Rewa, O., & Bagshaw, S. M. (2014) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.282 · Cited by 734
Jones, S. (2002) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(01)00155-8 · Cited by 488
Muller, P. Y., & Dieterle, F. (2009) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425250903114174 · Cited by 62
Cited by
Kidney-on-a-Chip technology for drug-induced nephrotoxicity screening
Wilmer, M. J., Ng, C. P., Lanz, H. L., Vulto, P., Suter-Dick, L., & Masereeuw, R. (2016) · Trends in Biotechnology · doi:10.1016/j.tibtech.2015.11.001 · Cited by 354
Drug Toxicity Evaluation Based on Organ-on-a-chip Technology: A Review
Cong, Y., Han, X., Wang, Y., Chen, Z., Lu, Y., Liu, T., Wu, Z., Jin, Y., Luo, Y., & Zhang, X. (2020) · Micromachines · doi:10.3390/mi11040381 · Cited by 140
“OPN (osteopontin) [35] Early detection biomarker ×”
Comparative Study of Multitask Toxicity Modeling on a Broad Chemical Space
Sosnin, S., Karlov, D., Tetko, I. V., & Fedorov, M. V. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00685 · Cited by 102
“7 However, due to their biological complexity, the in vitro tests do not also always provide a reliable estimation of the in vivo toxicity because human cell-based data used in in vivo testing may not take into account the general systemic toxicity for the whole organism.”
BackgroundSoucy, J. R., Bindas, A. J., Koppes, A. N., & Koppes, R. A. (2019) · iScience · doi:10.1016/j.isci.2019.10.052 · Cited by 62
Metadata
- Authors
- Huang, J. X., Blaskovich, M. A., & Cooper, M. A.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2014-11-10
- Volume
- 10
- Issue
- 12
- Pages
- 1621-1635
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2016752740
- Cited by
- 46
- References
- 9
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cell- and biomarker-based assays for predicting nephrotoxicity. https://app.cochat.ai/papers/10.1517/17425255.2014.967681
- The paper
- Huang, J. X., Blaskovich, M. A., & Cooper, M. A. (2014). Cell- and biomarker-based assays for predicting nephrotoxicity. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425255.2014.967681
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.